Our Focus

Our Approach

Building on GLP-1-based science to elevate the next era of obesity care

Our diversified GLP-1-based pipeline of clinical-stage therapeutic candidates is informed by decades of experience with GLP-1-based therapies and substantial research efforts and clinical data. Our approach seeks to expand upon proven science to advance product candidates which have the potential to maximize weight loss and address critical needs in the current therapeutic landscape while providing differentiated options for people living with obesity no matter where they are in their treatment journey.

Our obesity-first approach seeks to improve upon proven science with the goal of delivering category-leading obesity management medications for people living with obesity, no matter where they are in their treatment journey.

We are rapidly progressing four clinical-stage product candidates, leveraging multiple GLP-1-based mechanisms of action and oral and injectable routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/ GIP receptor dual agonist peptide.

We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation to provide a convenient oral option with the potential for highly differentiated tolerability and compelling weight loss. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments.

Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile.